Model N Enables Pharmaceutical Companies to Comply With the

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Model N Enables Pharmaceutical Companies to Comply With the AMP Final Rule

REDWOOD CITY, CA --(Marketwired - January 25, 2016) - Model N, Inc. ( NYSE : MODN ), the leading provider of cloud-based Revenue Management solutions to life science, technology and manufacturing companies, announces it will host a webinar to discuss the implications of the Affordable Care Act AMP Final Rule and a comprehensive strategy to comply with it. The webinar, titled "Strategies to Comply with the AMP Final Rule" is scheduled on Tuesday, February 2 at 10AM PT/ 1PM ET.

"The Final AMP Rule will dramatically alter the landscape of Medicaid price reporting and manufacturer rebate obligations," said John Shakow, a government price reporting expert at King & Spalding. "Manufacturers need to quickly assess the impact of the changes and act to update their systems and processes to comply with elements of this new final rulemaking."

Under current Medicaid requirements, all participating drug manufacturers must report AMP (Average Manufacturer Price) data for covered outpatient drugs to the Centers for Medicare & Medicaid Services (CMS) each month and quarter. A revised set of Medicaid regulations affecting AMP calculation as well as other important program requirements has been cleared by the Office of Management and Budget and will be published by CMS shortly. The AMP Final Rule dramatically transforms government compliance requirements in the pharmaceutical industry, and will have highly significant implications for manufacturers and their operations.

Regulatory change introduces complexity and organizational plus reputational risk, where incorrect pricing calculations can cause over or underpayments to the government resulting in revenue leakage and / or fines for noncompliance.

"In recent years, the pharmaceutical industry has gone through massive regulatory changes. The AMP Final Rule presents the next regulatory compliance risk for drug manufacturers," said Jesse Mendelsohn, Head of Center of Excellence at Model N. "Model N is ready and able to ensure our customers will be in compliance with the new regulations."

Model N recommends all pharmaceutical companies take these Five Steps now that the AMP Rule is final:

  1. Identify scope of change by joining the webinar on February 2 at 10AM PT
  2. Determine financial and operational impacts
  3. Build response plan with contingencies
  4. Execute plan, communicating results
  5. Document new current processes

To enable customers to rapidly identify, develop, test and deliver product enhancements to address regulatory changes, Model N created its Regulatory Update Program. Every Model N government compliance solution customer is automatically enrolled at no extra charge. The program includes robust resources, timely notifications, webinars, networking events and benchmarking studies.

To register for the webinar with John Shakow, please visit: http://pages.modeln.com/AMP-is-here_LP_RSVP.html

For more information on the AMP final ruling, visit http://www.modeln.com/verticals/life-sciences.../amp-rule/

About John Shakow

John Shakow is a partner in the FDA & Life Sciences Practice in the Washington, D.C., office of King & Spalding. His practice focuses on complex regulatory, commercial and litigation issues related to all aspects of drug pricing and price reporting. He counsels a diverse group of pharmaceutical and biotechnology manufacturer clients on all pricing-related rights and obligations under the Medicaid, Medicare, Federal Supply Schedule, 340B and TRICARE programs.

About Model N

Model N is the leader in Revenue Management Cloud solutions for life science, technology and manufacturing companies. Driving mission critical business processes such as configure, price and quote (CPQ), contract management, rebates and regulatory compliance. Model N Cloud solutions transform the revenue lifecycle from a series of disjointed operations into a strategic end-to-end process. With deep industry expertise, Model N supports the unique business needs of the world's leading brands in life science, technology and manufacturing companies across more than 100 countries.

Model N is a trusted partner to some of the world's largest brands, including Johnson & Johnson, AstraZeneca, Boston Scientific, Novartis, Ortho Clinical Diagnostics, Atmel, Fairchild and Marvell. Model N trades on the New York Stock Exchange under the symbol MODN.

Model N® is the registered trademark of Model N, Inc. Any other company names mentioned are the property of their respective owners and are mentioned for identification purposes only.

Image Available: http://www.marketwire.com/library/MwGo/2016/1...694bb2.jpg

Media Contact: Diandra Weldon Model N 650-610-4667 Dweldon@modeln.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Health Net Invests $3 Million in Stockton Housing

Updated Category News Views 145

Putting a Roof Over Stockton's Head The talk of the town in Stockton is Health Net stepping up with a $3 million investment. This isn't just dropping loose change in a jar; it's about tackling a mammoth issue—making affordable housing more than just a pipe dream for 75 families. Community-driven, they say. What a cozy way to paint a picture of bridging that brutal gap...

Continue Reading
Partner Joins Yardi ICN, Boosting Data Quality for Clients

Updated Category News Views 91

Strategic Alliances in Real Estate Data When Partner Engineering and Science, Inc. says they're hooking up with the Yardi Independent Consultant Network (ICN), that's not just some boardroom handshake. It's a play that could shake up data services in the real estate game. Look, there's plenty of chatter about digitizing property management, but without killer data, those...

Continue Reading
Dyania, NVIDIA Team Up: AI Transforming Patient Care

Updated Category News Views 61

Revving up efficiency in healthcare usually sounds like pie-in-the-sky talk, but every now and again, an innovation comes along that really stirs the pot. Enter Dyania Health's Synapsis AI, a clinical reasoning AI, teaming with NVIDIA's robust computing infrastructure. They're setting out to make sense of massive amounts of patient data, securely tucked behind a...

Continue Reading
D-Wave's 9.5% Drop: Fraud Lawsuit Raises Investor Ire

Updated Category News Views 101

Shockwaves from D-Wave's Earnings Call August wasn't exactly a banner month for D-Wave Quantum, Inc. as their stock went down like a lead balloon following a lackluster earnings report. If you've ever had any skin in the game, you'd know a 9.5% drop isn't just peanuts—it's the equivalent of watching your prized racehorse stumble at the first hurdle. The financials spoke...

Continue Reading
Euroandinos Paita Closes Consent for 2037 Notes

Updated Category News Views 70

Port Strategy and Financial Implications Terminales Portuarios Euroandinos Paita S.A., nestled in the Peruvian transport sector, has been tight-rope walking through its debt landscape. Announcing a successful consent solicitation on November 13, 2026, they've taken a significant step towards reconfiguring their long-term financing game. This puppet show of paperwork...

Continue Reading
PenFed Fuels Aggie Spirit with Blackout Game Activation

Updated Category News Views 156

A Different Kind of Game Day Experience Ah, there's nothing quite like the vibrancy of a Texas A&M game day, especially when it's a blackout event. On November 14, fans aren't just getting the good old college football thrills; they're diving headfirst into an extravaganza, courtesy of PenFed Credit Union. You might know them as the go-to credit union for military folks,...

Continue Reading
SmallRig Boosts Art-Driven Innovation in AI Era

Updated Category News Views 46

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Continue Reading
Fly-E Faces Revenue Drop Amid Retail Restructuring

Updated Category News Views 215

Downturn Despite Strategic Restructuring Today, we're diving into Fly-E Group, Inc. (NASDAQ:FLYE) and the latest shakeup in their financials—spoiler alert, it's riding a downward slope. Quarter two of fiscal 2027 didn't exactly shine a light on profitability. Net revenues slid, dropping to $2.6 million this quarter, down from $3.9 million the previous year. Tack that up...

Continue Reading
LA Fitness ELEVATE Opens at RITHM: A New Era Dawns

Updated Category News Views 66

Elevating Fitness at RITHM: A New Era Has Begun RD Management just dropped a new ace in Tampa Bay’s hand—LA Fitness ELEVATE at the RITHM at Uptown. They lit up the scene with this 30,000-square-foot beast of a gym, and I’ll tell you, it’s not your standard run-of-the-mill joint. When you toss twelve-and-a-half million bucks into a pot, you're aiming to lure folks...

Continue Reading
FiEE Rockets to Profitability with 382% Revenue Surge

Updated Category News Views 170

Big Moves in the Tech Jungle: FiEE's Comeback Let's chew the fat on FiEE, Inc., a company that's left its hardware-heavy past in the dust and grabbed the bull by the horns with fresh, AI-driven brand tech solutions. We're talking a whopping 382.1% revenue increase. Now, that's not chump change. From barely scraping $2 million last year to raking in $9.6 million just for...

Continue Reading

Top 5 Most Recently Viewed Articles

Cresilon Expands Reach with New VETIGEL Deal for Veterinarians

Updated Category News Views 267

Cresilon Partners with McCarthy Vet to Distribute VETIGEL Cresilon Inc., an innovative biotechnology firm known for its advanced hemostatic products, has announced a transformative agreement with McCarthy Vet. This collaboration marks a significant step forward as it allows for the distribution of VETIGEL, a groundbreaking hemostatic gel, directly to veterinary surgeons....

Continue Reading
Absci's Upcoming Financial Report and Business Highlights

Updated Category News Views 192

Absci Corporation's Upcoming Financial Reports Absci Corporation (Nasdaq: ABSI), recognized as a pioneer in data-driven generative AI for drug discovery, is gearing up to release important business updates along with financial results for the first quarter of 2025. This report is scheduled to be unveiled subsequent to market close. Key Highlights of the Upcoming Report...

Continue Reading
Upcoming Q2 2025 Results Announcement by Borregaard ASA

Updated Category News Views 186

Borregaard ASA's Second Quarter Results Announcement Borregaard ASA, a renowned name in biochemistry, is set to present its Q2 2025 results. This event will take place on Wednesday, coinciding with July 16, 2025, at 07:00 CEST. As anticipated, a comprehensive stock exchange announcement will follow shortly thereafter. What to Expect from the Presentation The presentation...

Continue Reading
JP Conte's Lupine Crest Pours $14M into Orizon Again

Updated Category News Views 29

JP Conte's Bet on Brazilian Waste-to-Energy Giant Here's the scoop, folks. Lupine Crest Capital, helmed by none other than JP Conte, just doubled down on their investment in Brazil. This isn't some negligible penny-ante increase, but a hefty infusion of R$70 million—think roughly $14 million in USD—into Orizon Valorização de Resíduos S.A., the notable...

Continue Reading
Hedge Funds Shift Strategies Amid Volatile U.S. Equity Markets

Updated Category News Views 121

Hedge funds adjusted their playbooks back then in 2023, net selling equities amid a flurry of options expiry and index rebalancing. The desks were abuzz as they noted slight selling pressure from these funds, yet after the dust settled on that chaotic week, buying picked up noticeably—especially Thursday when it seemed traders found some footing again. Macro Products...

Continue Reading